Archives of Virology

, Volume 162, Issue 11, pp 3283–3291 | Cite as

Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin

  • Dalia S. Elhelw
  • Sarah E. Riad
  • Heba Shawer
  • Nada El-Ekiaby
  • Ayman Salah
  • Abdelrahman Zekri
  • Asma Amleh
  • Gamal Esmat
  • Ahmed Ihab Abdelaziz
Original Article

Abstract

Occludin (OCLN) is an essential factor for HCV entry through interacting with other surface receptors. The aim of this study was to investigate the epigenetic regulation of Occludin expression and to study its impact on viral infectivity. microRNAs expression was assessed using qRT-PCR, while OCLN protein expression was investigated by indirect immunofluorescence and Western blotting. Viral infectivity was assessed by measuring viral-load using qRT-PCR. In silico analysis predicted that miR-200c targeted the OCLN 3’UTR, which was further experimentally confirmed. miR-122 was previously validated to target the 3’UTR of OCLN and was used as a control. We report a significant down-regulation of miR-200c in liver tissues of HCV-infected patients. Ectopic expression of both miR-122 and miR-200c in Huh7 cells reduced OCLN mRNA and protein levels. Viral infectivity was significantly reduced by miR-200c but enhanced by miR-122. This work sheds light on miR-200c as a novel regulator of HCV infectivity through the regulation of OCLN.

Notes

Acknowledgements

The authors would like to thank Prof. Jens Bukh and Prof. Wakita for providing us with JFH1 and ED43/JFH1HCV constructs, respectively.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S et al (1993) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123(6 Pt 2):1777–1788CrossRefPubMedGoogle Scholar
  2. 2.
    Cummins PM (2012) Occludin: one protein, many forms. Mol Cell Biol 32(2):242–250. doi: 10.1128/MCB.06029-11 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chiba H, Osanai M, Murata M, Kojima T, Sawada N (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778(3):588–600. doi: 10.1016/j.bbamem.2007.08.017 CrossRefPubMedGoogle Scholar
  4. 4.
    Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP et al (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231):882–886. doi: 10.1038/nature07684 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV et al (2011) Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 85(1):596–605. doi: 10.1128/JVI.01592-10 CrossRefPubMedGoogle Scholar
  6. 6.
    Pietschmann T (2009) Virology: final entry key for hepatitis C. Nature 457(7231):797–798. doi: 10.1038/457797a CrossRefPubMedGoogle Scholar
  7. 7.
    Sourisseau M, Michta ML, Zony C, Israelow B, Hopcraft SE, Narbus CM et al (2013) Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog 9(3):e1003244. doi: 10.1371/journal.ppat.1003244 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL, Lavillette D, Prieto J et al (2009) The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 83(16):8012–8020. doi: 10.1128/JVI.00038-09 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z et al (2014) MiR-181a regulates blood-tumor barrier permeability by targeting Kruppel-like factor 6. J Cereb Blood Flow Metab 34(11):1826–1836. doi: 10.1038/jcbfm.2014.152 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ye D, Guo S, Al-Sadi R, Ma TY (2011) MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 141(4):1323–1333. doi: 10.1053/j.gastro.2011.07.005 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sendi H, Mehrab-Mohseni M, Foureau DM, Ghosh S, Walling TL, Steuerwald N et al (2015) MiR-122 decreases HCV entry into hepatocytes through binding to the 3’ UTR of OCLN mRNA. Liver Int 35(4):1315–1323. doi: 10.1111/liv.12698 CrossRefPubMedGoogle Scholar
  12. 12.
    Helle F, Dubuisson J (2008) Hepatitis C virus entry into host cells. Cell Mol Life Sci 65(1):100–112. doi: 10.1007/s00018-007-7291-8 CrossRefPubMedGoogle Scholar
  13. 13.
    Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T (2009) Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83(4):2011–2014. doi: 10.1128/JVI.01888-08 CrossRefPubMedGoogle Scholar
  14. 14.
    Oliveira KG, Malta FM, Nastri AC, Widman A, Faria PL, Santana RA et al (2016) Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 205(2):111–117. doi: 10.1007/s00430-015-0431-0 CrossRefPubMedGoogle Scholar
  15. 15.
    Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP et al (2008) MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47(4):1223–1232. doi: 10.1002/hep.22158 CrossRefPubMedGoogle Scholar
  16. 16.
    Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D (2013) Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52(4):297–303. doi: 10.1002/mc.21864 CrossRefPubMedGoogle Scholar
  17. 17.
    Liu Z, Yi J, Ye R, Liu J, Duan Q, Xiao J et al (2015) miR-144 regulates transforming growth factor-beta1 iduced hepatic stellate cell activation in human fibrotic liver. Int J Clin Exp Pathol 8(4):3994–4000PubMedPubMedCentralGoogle Scholar
  18. 18.
    Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309(5740):1577–1581. doi: 10.1126/science.1113329 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria 2017

Authors and Affiliations

  • Dalia S. Elhelw
    • 1
  • Sarah E. Riad
    • 2
  • Heba Shawer
    • 3
  • Nada El-Ekiaby
    • 2
  • Ayman Salah
    • 4
  • Abdelrahman Zekri
    • 5
  • Asma Amleh
    • 3
  • Gamal Esmat
    • 6
  • Ahmed Ihab Abdelaziz
    • 2
    • 3
  1. 1.Department of Pharmaceutical ChemistryGerman University in CairoNew CairoEgypt
  2. 2.Department of Pharmacology and ToxicologyGerman University in Cairo, GUC New Cairo CityNew CairoEgypt
  3. 3.School of MedicineNewGiza University (NGU)CairoEgypt
  4. 4.Department of SurgeryCairo UniversityCairoEgypt
  5. 5.Virology and Immunology Unit, Cancer Biology Department, National Cancer InstituteCairo UniversityCairoEgypt
  6. 6.Department of Endemic Medicine and HepatologyCairo UniversityCairoEgypt

Personalised recommendations